pdgfra ie plateletderiv growth factor receptor also term pdgfr ie plateletderiv growth factor receptor cda ie cluster differenti receptor locat surfac wide rang cell type receptor bind certain isoform plateletder growth factor pdgfs therebi becom activ stimul cell signal pathway elicit respons cellular growth differenti receptor critic develop certain tissu organ embryogenesi mainten tissu organ particular hematolog tissu throughout life mutat gene code pdgfra ie pdgfra gene associ array clinic signific neoplasm gene encod typic receptor tyrosin kinas transmembran protein consist extracellular ligand bind domain transmembran domain intracellular tyrosin kinas domain molecular mass matur glycosyl pdgfr protein approxim kda cell surfac tyrosin kinas receptor member plateletderiv growth factor famili activ pdgfr requir derepress receptor kinas activ ligand pdgfr pdgf accomplish cours assembl pdgfr dimer four five pdgf isoform activ pdgfr pdgfa pdgfb pdgfab pdgfc activ receptor phosphoryl protein therebi engag intracellular signal pathway trigger cellular respons migrat prolifer also pdgfindepend mode derepress pdgfrs kinas activ henc activ instanc forc pdgfr close proxim overexpress antibodi direct extracellular domain altern mutat kinas domain stabil kinas activ conform result constitut activ final growth factor outsid pdgfr famili nonpdgf activ pdgfr indirect nonpdgf bind receptor trigger intracellular event derepress kinas activ pdgfr monom intracellular event nonpdgf indirect activ pdgfr includ elev reactiv oxygen speci activ src famili kinas phosphoryl pdgfr mode activ determin durat pdgfr remain activ pdgfmediat mode dimer pdgfr acceler intern degrad activ pdgfr halflif pdgfactiv pdgfr approxim min endur activ pdgfr halflif great min occur pdgfr monom activ import pdgfra develop appar observ major mous lack function pdgfra gene develop plethora embryon defect lethal mutant mous exhibit defect kidney glomerulus lack mesangi cell also suffer illdefin blood defect character thrombocytopen bleed tendenc sever anemia could due blood loss mous die short birth pdgfa pdgfc seem import activ pdgfr develop mous lack function gene pdgfra activ ligand ie pdgfapdgfc doubl null mous show similar defect pdgra null mous mous genet engin express constitut ie continu activ pdgfr mutant receptor eventu develop fibrosi skin multipl intern organ studi suggest pdgfra play fundament role develop function mesoderm tissu eg blood cell connect tissu mesangi cell somat mutat caus fusion pdgfra gene certain gene occur hematopoiet stem cell caus hematolog malign clonal hypereosinophilia class malign mutat creat fuse gene encod chimer protein possess continu activ pdgfrader tyrosin kinas therebi continu stimul cell growth prolifer lead develop leukemia lymphoma myelodysplast syndrom common associ hypereosinophilia therefor regard subtyp clonal eosinophilia common mutat pdgfra gene human chromosom posit notat fuse fipl gene also locat posit interstiti ie chromosom fusion creat fiplpdgfra fusion gene usual lose interven genet materi typic includ either chic lnx gene fuse gene encod fiplpdgfra protein caus chronic eosinophilia progress chronic eosinophil leukemia form myeloprolif neoplasmmyeloblast leukemia associ littl eosinophilia tlymphoblast leukemialymphoma associ eosinophilia myeloid sarcoma eosinophilia see fiplpdgfra fusion gene mixtur present variat type malign form like reflect specif type hematopoiet stem cell bear mutat pdgfra gene may also mutat one sever chromosom transloc creat fusion gene like fiplpdgfra fusion gene encod fusion protein possess continu activ pdgfrarel tyrosin kinas caus myeloid andor lymphoid malign mutat includ fiplpdgfra mutat along chromosom locat pdgfra partner notat use identifi fuse gene give follow tabl patient afflict one transloc mutat similar afflict interstiti pdgfrafipl fusion gene present find chronic eosinophilia hypereosinophilia hypereosinophil syndrom chronic eosinophil leukemia myeloprolif neoplasmmyeloblast leukemia tlymphoblast leukemialymphoma myeloid sarcoma diagnos cytogenet usual analysi detect breakpoint short arm chromosom use fluoresc situ hybrid treat mani transloc extrem rare fulli test drug sensit respond well anticip respond well imatinib therapi describ treatment diseas caus fiplpdgfra fusion gene activ mutat pdgfra also involv develop common mesenchym neoplasm gastrointestin tract gi tract viz gastrointestin stromal tumor gist gist tumor sarcoma deriv gi tract connect tissu wherea gi tract tumor adenocarcinoma deriv tract epithelium cell gist tumor occur throughout gi tract occur stomach develop low malign potenti gist tumor find elsewher gi tract common pdgfra mutat find gist tumor occur exon think stabil pdgfra tyrosin kinas activ conform singl mutat dv exon account gist tumor next common gist tumor mutat occur exon account gist tumor delet codon exon second common mutat pdgfra exon gist find gist tumor mutat pdgfra exon find gist tumor pdgfra mutationinduc gist tumor sensit tyrosin kinas inhibitor imatinib common mutat dv well rare mutat resist drug median overal surviv report month patient whose tumor bear dv mutat compar month larg seri imatinibtr patient type gist mutat consequ critic defin exact natur pdgfrinduc mutant gist tumor order select appropri therapi particular novel pdgfra select kinas inhibitor crenolanib investig treat dvinduc imatinibresist gist tumor random trial test efficaci crenolanib patient gist tumor bear dv mutat recruit olaratumab ly human igg monoclon antibodi design bind human pdgfr high affin block pdgfaa pdgfbb pdgfcc ligand bind receptor numer studi use treat soft tissu sarcoma includ gist ongo studi gist focus inoper metastat andor recurr diseas test olagatumab doxorubicin versus doxorubicin along fda grant approv use olaratumabdcoxorbicin therapi soft tissu sarcoma acceler approv program base result phase ii trial nct addit european medicin agenc grant condit approv olaratumab indic novemb follow review ema acceler assess program gainoffunct hkm mutat protein histon lead inactiv polycomb repress complex prc methyltransferas result global hypomethyl hkme transcript derepress potenti oncogen mutat associ gain function amplif mutat pdgfra gene case pediatr diffus glioma pon appear initi histon mutat alon insuffici rather requir cooper secondari mutat pdgfraactiv mutat pdgfra amplif develop type brain tumor small nonrandom trial studi imatinib therapi patient glioblastoma select basi imatinibinhibit tyrosin kinas biopsi tissu caus margin diseas improv compar similar treatment patient unselect recurr glioblastoma suggest patient subpopul excess pdgfrarel tyrosin kinaserel overact might benefit imatinib therapi sever phase phase ii clinic gliomaglioblastoma studi conduct use imatinib decis followup phase iii studi report pdgfra show interact articl incorpor text unit state nation librari medicin public domain